Mylan has been accused of underpaying Medicaid in rebates for EpiPens, and agreed to pay $465 million to the government to resolve such claims. » Read More
John Crowley, CEO of Amicus Therapeutics, discusses his biotechnology business model, as well as drugs pricing.
Mark Hooper, CEO at Sigma Pharmaceuticals, talks about how his company leveraged on e-commerce to enter the Chinese market.
Volatility in the healthcare sector could increase as hedging on healthcare stocks becomes more popular, says WBB Securities' Steve Brozak.
David Maris, Wells Fargo Securities, discusses where he foresees trouble in the biotech sector, as well finding safety in these cases.
Federal health officials and the drug company Mylan are refusing to explain why full rebates for EpiPen are being delayed.
CNBC's Meg Tirrell reports the latest trouble in the biotech sector, specifically involving Illumina and Theranos.
Illumina shares sink after the company trimmed its third-quarter revenue projections.
Rich Ross, Evercore ISI, goes off the charts to take a look at three stocks set for a breakout.
Michael Yee, RBC Capital Markets biotech analyst, shares his take on big biotech movers including Mylan, Tesaro and more.
CNBC's Meg Tirrell reports the latest in biotech, including what is next for Mylan following the company's EpiPen settlement with the U.S. Department of Justice.
Mylan has been under fire for months over sky-high price hikes of anti-allergy EpiPen devices.
CNBC's Meg Tirrell reports on the moves in cancer drugmakers following the European Cancer Congress in Copenhagen. The "FMHR" traders weigh in.
Elliot Wilbur, Raymond James, discusses his call to upgrade Mylan to buy based on valuation.
Raymond James on Monday upgraded shares of Mylan to strong buy from market perform, citing valuations that have reached a multidecade low.
Mylan soared Monday after it agreed to pay $465 million to settle charges that it overcharged the government for its EpiPen products.
Mylan agreed Friday to a $465 million settlement over the classification of its anti-allergy EpiPen auto-injector under the Medicaid Drug Rebate program.
Get the best of CNBC in your inbox